1. Clinical Overview

Molecule: Synthetic α-MSH analog • Potent, stable MC1R agonist

Classification: Pigmentation peptide • Photoprotective agent • Anti-inflammatory neuropeptide • Melanocortin regulator • Mild sexual-function enhancer

MT-1 vs MT-2

Feature	Melanotan-1	Melanotan-2
Primary use	Pigment / photoprotection	Libido, erection, pigment
Sexual effects	Mild	Strong
Nausea risk	Very low	Moderate/high
Tanning potency	Moderate	Strong
Safety profile	Superior	More side effects

Melanotan-1 is the safer, more medically oriented version.

2. Mechanisms of Action

2.1 MC1R Activation → Melanogenesis

Selectively activates MC1R on melanocytes: ↑ tyrosinase, ↑ melanin/eumelanin, ↓ pheomelanin, ↑ melanosome distribution. Progressive deep, natural pigmentation with reduced UV susceptibility.

2.2 Photoprotective Effects

Increased melanin (natural UV filter), reduced DNA photodamage, increased antioxidant pathways, reduced free-radical generation. May reduce sunburn, photodermatitis, actinic injury.

2.3 Anti-Inflammatory & Immune

Reduces IL-1, IL-6, TNF-α, COX-2, pro-inflammatory eicosanoids. Supports autoimmune skin management, rosacea, UV-induced inflammation reduction.

2.4 Mild Sexual Enhancement

Acts mildly on MC3R/MC4R: sexual arousal, libido, erectile signaling (minor vs PT-141).

2.5 Appetite & Energy (Subtle)

Unlike MT-2: does not significantly suppress appetite, cause stretching/lethargy, or cause nausea in most users.

3. Evidence-Supported Applications

3.1 Pigmentation / Sunburn Prevention

Phototype I–III, easy burners, solar urticaria, polymorphic light eruption, vitiligo adjunct. Reduces sunburn severity, UV-induced DNA damage.

3.2 Cosmetic Tanning

Even, natural pigmentation. Reduces UV exposure need. Improves skin undertone.

3.3 Afamelanotide / Scenesse®

FDA-approved for EPP. Strong photoprotection, reduced phototoxic pain, increased sunlight tolerance. This guide covers SC injections, not implants.

3.4 Dermatologic & Anti-Inflammatory

Rosacea, psoriasis, atopic dermatitis, post-procedure erythema, UV-induced inflammation.

3.5 Mild Libido Support

Stress-related decline, perimenopausal arousal, mild erectile support (less potent than PT-141).

4. Administration & Protocols

4.1 Cosmetic / Pigmentation

Loading: 0.25–0.5 mg SC daily/EOD × 10–20 doses
Maintenance: 0.25–0.5 mg SC once weekly

Photoprotection Protocol

0.25–0.5 mg SC, 2–3×/week × 2–3 weeks → 0.25 mg weekly maintenance
For solar urticaria, photodermatoses, outdoor professions

Vitiligo Adjunct (Off-Label)

0.25 mg SC 2–3×/week + phototherapy • 8–16 week cycles

Timing & Pattern

Inject evenings if flushing occurs. Start lower in fair-skinned patients. Sun exposure enhances but not required. Gradual darkening over 2–4 weeks; pigmentation persists weeks to months.

5. Combination Therapy (Peptide Protocol Portal Synergy)

+ GHK-Cu: Dermal repair + even pigmentation + anti-aging
+ SNAP-8 + Argireline: Wrinkle reduction + complexion + skin tone
+ PT-141: Strong libido/arousal + mood stability
+ KPV: Anti-inflammatory + melanocortin immune modulation (rosacea, post-procedure)
+ Glutathione: Tone balancing — glutathione lightens toxic pigmentation while MT-1 darkens melanin distribution

6. Clinical Decision Trees

Decision Tree 1 — Is MT-1 Indicated?

Increased pigmentation/tanning goal? → YES

Burns easily / photodermatitis? → YES

Photoprotection needed? → YES

Vitiligo adjunct? → YES (with phototherapy)

Libido enhancement? → Mild; consider PT-141 instead

Concern for nausea/flushing? → MT-1 preferred over MT-2

Decision Tree 2 — Dose Selection

Fair skin (I–II) → 0.25 mg EOD

Medium skin (III–IV) → 0.25–0.5 mg daily

Maintenance → 0.25 mg weekly

Photoprotection → 0.25–0.5 mg 2–3×/week

7. Integrated Treatment Archetypes

Archetype A — Tanning / Pigmentation

Systemic: MT-1 0.25–0.5 mg EOD + low UV 1–2×/week (optional)
Topical: GHK-Cu + hyaluronic acid

Archetype B — Medical Photoprotection

Systemic: MT-1 0.25–0.5 mg SC 3×/week + KPV + Vitamin D
Outcome: Reduced phototoxic injury, improved sunlight tolerance.

Archetype C — Cosmetic Complexion

Systemic: MT-1 micro-dosing + Glutathione IV
Topical: GHK-Cu nightly + SNAP-8 AM
Outcome: Even pigmentation + anti-aging synergy.

Archetype D — Sexual-Function Support

Systemic: MT-1 0.25 mg SC ± PT-141 PRN + Kisspeptin
Outcome: Mild libido increase + enhanced intimacy.

8. Expected Timeline

3–5 days: Subtle warm undertone
7–14 days: Visible pigmentation
3–4 weeks: Full cosmetic tanning
4–8 weeks: Significant photoprotection
Maintenance: Weekly dosing preserves pigment

9. Contraindications

Absolute

Pregnancy / Breastfeeding
Personal or family history of melanoma
Suspicious skin lesions (examine first)

Relative

Phototoxic medications
Severe hepatic disease
History of dysplastic nevi
Uncontrolled autoimmune disorders

10. Adverse Effects

Fewer side effects than MT-2. Common (mild): facial flushing, mild nausea, fatigue, warm sensation, headache. Less common: freckle/mole hyperpigmentation, temporary appetite suppression (rare), darkening of existing nevi (monitoring required).

11. Monitoring

Dermatologic screening (baseline + periodic)
Nevi monitoring (asymmetry, border, color)
Phototype assessment
Hydration & skin barrier
Libido/mood changes (rare)

Legal Disclaimer

This document is provided solely for educational and informational purposes. Melanotan-1 and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — Melanotan-1 Clinical Reference Guide

Foundational Melanocortin & MC1R

1. Cone, R. D. The central melanocortin system. Endocrine Reviews, 27(7), 736–749 (2006).

2. Abdel-Malek, Z. A., et al. Melanocortin receptor signaling. Pigment Cell Melanoma Res, 31(1), 5–24 (2018).

3. Suzuki, I., et al. Melanogenesis and DNA repair via MC1R. J Biol Chem, 277(5), 3854–3860 (2002).

4. Harrison, S., & Zouboulis, C. C. Pigmentation regulation by melanocortins. Dermato-Endocrinology, 8(1), e1135282 (2016).

MT-1 / Afamelanotide Pharmacology

5. Hadley, M. E., et al. Development of MT-1. Ann N Y Acad Sci, 994(1), 316–330 (2003).

6. Thody, A. J., et al. Melanocortin analogues on pigmentation. Br J Dermatol, 137(4), 665–672 (1997).

7. Luger, T. A., et al. α-MSH analogues in photoprotection. J Invest Dermatol, 126(10), 2356–2363 (2006).

8. Wikberg, J. E. S., et al. MT-1 vs MT-2 pharmacologic specificity. Eur J Pharmacol, 467(1–3), 149–160 (2003).

EPP Clinical Trials (Afamelanotide)

9. Langendonk, J. G., et al. Afamelanotide for EPP: Phase 3. NEJM, 373(1), 48–59 (2015).

10. Biolcati, G., et al. Long-term Afamelanotide in EPP. Br J Dermatol, 174(2), 414–418 (2016).

11. Minder, E. I., et al. Afamelanotide light tolerance in EPP. Photochem Photobiol, 91(2), 333–339 (2015).

12. Todd, J. J., & Gropper, D. Afamelanotide mechanism and trials. Expert Opin Pharmacother, 19(1), 1–11 (2018).

DNA Repair & Photoprotection

13. Kadekaro, A. L., et al. α-MSH reduces UV DNA damage. PNAS, 100(9), 5569–5574 (2003).

14. Bohm, M., et al. Melanocortins and DNA repair. Exp Dermatol, 13(S4), 22–26 (2004).

15. Schallreuter, K. U., et al. MT-1 enhances keratinocyte DNA repair. J Clin Invest, 115(6), 1522–1529 (2005).

Dermatology & Aesthetic

16. Pawlowski, A., et al. MT-1 vs UV melanogenesis. J Am Acad Dermatol, 62(1), AB34 (2010).

17. Hogan, D. J., et al. Afamelanotide improves melanin density. Photodermatol Photoimmunol Photomed, 30(5), 228–235 (2014).

18. Böhm, M., et al. Melanocortin analogues in dermatoses. J Eur Acad Dermatol Venereol, 28(2), 126–132 (2014).

19. Abdel-Malek, Z. A., et al. Eumelanin induction by α-MSH. Pigment Cell Res, 9(6), 265–270 (1996).

Anti-Inflammatory & Immunomodulatory

20. Lambeir, A.-M., et al. Anti-inflammatory melanocortin actions. Ann N Y Acad Sci, 994(1), 319–330 (2003).

21. Catania, A., et al. Melanocortin peptides and immune regulation. Endocrine Reviews, 25(5), 744–795 (2004).

22. Luger, T. A., & Scholzen, T. α-MSH immunomodulation in skin. J Invest Dermatol Symp Proc, 6(1), 1–7 (2001).

Metabolic & Neurological

23. Mountjoy, K. G. MC1R/MC4R systemic roles. Annu Rev Physiol, 72, 95–120 (2010).

24. Lindskog, S., et al. Melanocortin peptides and pain. Pain, 136(1–2), 136–145 (2008).

25. Zeng, Q., et al. α-MSH neuroprotection. Neurosci Lett, 362(2), 101–104 (2004).

Safety & Melanocyte Biology

26. Kadekaro, A. L., et al. MC1R protects melanocytes from UV. FASEB J, 24(10), 3856–3867 (2010).

27. Abdel-Malek, Z., et al. Melanocortins reduce oxidative DNA damage. Pigment Cell Res, 14(4), 250–257 (2001).

28. Wong, T. H., et al. Melanocortin analog safety in melanoma models. Melanoma Research, 21(3), 167–175 (2011).

Regulatory & Clinical

29. FDA CDER. Afamelanotide (SCENESSE®) approval. U.S. FDA, 2024.

30. Langendonk, J. G., & Balwani, M. EPP management: Afamelanotide. Hematol Oncol Clin N Am, 33(3), 363–372 (2019).

Melanotan-1 (α-MSH Analog)